文献速递冠心病

急性心肌梗死早期排除路径的疗效与安全性比较

Comparison of the Efficacy and Safety of Early Rule-Out Pathways for Acute Myocardial Infarction.
PubMed 文献 · Circulation · 2016-12-29

在1218例疑似急性冠脉综合征患者中比较欧洲心脏病学会排除路径与High-STEACS路径,High-STEACS路径在就诊时排除40.7%患者、阴性预测值99.5%,优于欧洲心脏病学会路径的28.1%和97.9%,且漏诊的指数心肌梗死少5倍。

要点

  • High-STEACS路径在就诊时排除40.7%患者,阴性预测值99.5%。
  • 欧洲心脏病学会路径就诊时排除28.1%,阴性预测值97.9%。
  • High-STEACS路径漏诊2例指数事件,欧洲心脏病学会路径漏诊18例。

核心结论

  • 采用低高敏肌钙蛋白浓度的High-STEACS路径在就诊时排除心肌梗死的患者更多,漏诊的指数心肌梗死比仅基于第99百分位的指南批准路径少5倍。

研究设计与样本

  • 疑似急性冠脉综合征患者1218例,就诊时及3小时和6或12小时测量高敏肌钙蛋白I。
  • 比较欧洲心脏病学会路径与High-STEACS研究人群开发的路径。
  • 主要结局为两种路径对指数1型心肌梗死或30天内1型心肌梗死或心源性死亡的阴性预测值比较。
  • 在年龄、性别、症状发作时间和已知缺血性心脏病预设亚组中评估主要结局。

主要发现

  • 主要结局发生于15.7%(191/1218)患者。
  • 就诊时低于第99百分位者中,欧洲心脏病学会路径在就诊时和3小时分别排除28.1%(342/1218)和78.9%(961/1218),漏诊18例指数事件和2例30天事件,阴性预测值97.9%(95%CI 96.9-98.7)。
  • High-STEACS路径在就诊时和3小时分别排除40.7%(496/1218)和74.2%(904/1218),漏诊2例指数事件和2例30天事件,阴性预测值99.5%(95%CI 99.0-99.9;比较P<0.001)。
  • High-STEACS路径的阴性预测值总体高于欧洲心脏病学会路径(P<0.001),在所有亚组中亦如此,包括早期就诊或已知缺血性心脏病者。

关键数值与推荐

  • 欧洲心脏病学会路径:就诊时或症状<6小时时3小时<第99百分位。
  • High-STEACS路径:就诊时<5 ng/L或3小时变化<3 ng/L且<第99百分位。
  • High-STEACS路径阴性预测值99.5%(95%CI 99.0-99.9)vs 欧洲心脏病学会路径97.9%(95%CI 96.9-98.7),比较P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-sensitivity cardiac troponin assays enable myocardial infarction to be ruled out earlier, but the optimal approach is uncertain. We compared the European Society of Cardiology rule-out pathway with a pathway that incorporates lower cardiac troponin concentrations to risk stratify patients. METHODS: Patients with suspected acute coronary syndrome (n=1218) underwent high-sensitivity cardiac troponin I measurement at presentation and 3 and 6 or 12 hours. We compared the European Society of Cardiology pathway (<99th centile at presentation or at 3 hours if symptoms <6 hours) with a pathway developed in the High-STEACS study (High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome) population (<5 ng/L at presentation or change <3 ng/L and <99th centile at 3 hours). The primary outcome was a comparison of the negative predictive value of both pathways for index type 1 myocardial infarction or type 1 myocardial infarction or cardiac death at 30 days. We evaluated the primary outcome in prespecified subgroups stratified by age, sex, time of symptom onset, and known ischemic heart disease. RESULTS: The primary outcome occurred in 15.7% (191 of 1218) patients. In those less than the 99th centile at presentation, the European Society of Cardiology pathway ruled out myocardial infarction in 28.1% (342 of 1218) and 78.9% (961 of 1218) at presentation and 3 hours, respectively, missing 18 index and two 30-day events (negative predictive value, 97.9%; 95% confidence interval, 96.9-98.7). The High-STEACS pathway ruled out 40.7% (496 of 1218) and 74.2% (904 of 1218) at presentation and 3 hours, missing 2 index and two 30-day events (negative predictive value, 99.5%; 95% confidence interval, 99.0-99.9; P<0.001 for comparison). The negative predictive value of the High-STEACS pathway was greater than the European Society of Cardiology pathway overall (P<0.001) and in all subgroups, including those presenting early or known to have ischemic heart disease. CONCLUSIONS: Use of the High-STEACS pathway incorporating low high-sensitivity cardiac troponin concentrations rules out myocardial infarction in more patients at presentation and misses 5-fold fewer index myocardial infarctions than guideline-approved pathways based exclusively on the 99th centile. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT01852123.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chapman AR, Anand A, Boeddinghaus J, et al. Comparison of the Efficacy and Safety of Early Rule-Out Pathways for Acute Myocardial Infarction. Circulation. 2016. PMID: 28034899. doi:10.1161/CIRCULATIONAHA.116.025021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。